Efficacy and safety of Canagliflozin (CANA), an inhibitor of Sodium Glucose Co-Transporter 2 (SGLT2), added on to insulin therapy with or without oral agents in type 2 diabetes (T2D)

Abstract

Question: SGLT2 inhibition is a novel treatment modality for T2D. We report here a pre-specified substudy of the CANagliflozin cardioVascular Assessment Study (CANVAS) defining the efficacy and safety of CANA in subjects with T2D on insulin.